Biotechnology
Overcoming Resistance and Toxicity Hurdles: PST's Localized Drug Delivery Technology May Unlock Combined MEK/mTOR Inhibition For Multiple KRAS+ Tumors Types
Share
IRVINE, Calif., May 23, 2024 /PRNewswire/ -- Postsurgical Therapeutics, Inc. (PST) today announced the successful completion of an in vivo study of its proprietary injectable gel formulation containing two drugs used to treat several types of KRAS mutated solid tumors. The results demonstrated suppression or elimination of tumors in mice. The drugs were developed and commercialized by others for oral administration.
PST's proprietary controlled release gel formulation of the drugs was administered by intratumoral injection to the target tumors. The drugs used target the MAPK and PI3K pathways using a combination of MEK and mTOR inhibitors, which are important for treatment of several major tumor types. The formulation was shown to be effective, reducing growth or eradicating tumors in several KRAS mutations across multiple cancer cell lines, including pancreatic (Mia PaCa-2, G12C), lung (NCI H441, G12V), colorectal (SW3, G12V), and gastric (AGS, G12D) cancers.
In clinical practice, multiple drugs are often required as resistance to a single drug limits its therapeutic use. However, clinic investigations by others of combinations of these two drugs by oral administration have not been able to determine a safe and effective dose due to cumulative toxicity as reported by Tolcher (Tolcher et al. Annals of Oncology, 58-64 (2015)) and by Nikanjam (Nikanjam et al. J. Hematol. Oncol. Pharm, 19-25 (2023)).
Soonkap Hahn, Ph.D., Chairman, Chief Scientific Officer, and Founder of PST stated that "If clinical trials confirm the results of this study, we believe the resulting product will have the potential to extend the lives of treated patients. We will also investigate the potential reduction in toxicity by local administration."
PST is a development stage company based in Irvine, California. PST uses advanced drug delivery technologies to formulate products with enhanced efficacy and safety for the treatment of solid tumors and other therapy areas.
PST intends to develop and commercialize products based on its technology through collaborations with corporate partners and others.
View original content to download multimedia:https://www.prnewswire.com/news-releases/overcoming-resistance-and-toxicity-hurdles-psts-localized-drug-delivery-technology-may-unlock-combined-mekmtor-inhibition-for-multiple-kras-tumors-types-302153627.html
SOURCE Postsurgical Therapeutics
First published on Thu, May 23, 2024
Enjoyed what you read? Great news – there’s a lot more to explore!
Dive into our content repository of the latest tech news, a diverse range of articles spanning introductory guides, product reviews, trends and more, along with engaging interviews, up-to-date AI blogs and hilarious tech memes!
Also explore our collection of branded insights via informative white papers, enlightening case studies, in-depth reports, educational videos and exciting events and webinars from leading global brands.
Head to the TechDogs homepage to Know Your World of technology today!
Disclaimer - Reference to any specific product, software or entity does not constitute an endorsement or recommendation by TechDogs nor should any data or content published be relied upon. The views expressed by TechDogs' members and guests are their own and their appearance on our site does not imply an endorsement of them or any entity they represent. Views and opinions expressed by TechDogs' Authors are those of the Authors and do not necessarily reflect the view of TechDogs or any of its officials. While we aim to provide valuable and helpful information, some content on TechDogs' site may not have been thoroughly reviewed for every detail or aspect. We encourage users to verify any information independently where necessary.
Trending PR Newswire
Propelr Named One Of 2025'S Best Enterprise LMS Platforms By Talented Learning
24 Exchange Appoints Gina Tuccio As Chief Financial Officer
Cyble And Botswana Communications Regulatory Authority (BOCRA) Sign Mou To Advance National Cybersecurity In Botswana
HOPPR Introduces Its AI Foundry: A Scalable, Secure Platform Accelerating The Development Of AI In Medical Imaging
Kia's All-Electric PV5 Secures Industry's Most Prestigious LCV Award
Join Our Newsletter
Get weekly news, engaging articles, and career tips-all free!
By subscribing to our newsletter, you're cool with our terms and conditions and agree to our Privacy Policy.
Join The Discussion